Fenofibrate drug found to reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of good cholesterol, finds a new study funded by the National Heart, Lung, and Blood Institute (NHLBI).
The research study is published in the journal JAMA Cardiology.
Fenofibrate is primarily used to help reduce elevated levels of triglycerides, or fat, in the blood. But the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes. People with type 2 diabetes are at high risk of cardiovascular-related events, such as heart attacks, stroke, and even death, often because their levels of triglycerides are so high, and their high-density lipoprotein (HDL) cholesterol levels are low.